Lenz, Heinz-Josef

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 2,895

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 2,836

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 2,079

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy

Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews

Chemokine receptors and signalingCancer Immunotherapy and Biomarkers

Cited by 1,627

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 1,431

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 898

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 789

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 709

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer

Pomerantz, M. M., Ahmadiyeh, N., Jia, L., Herman, P., Verzi, M. P., Doddapaneni, H., Beckwith, C. A., Chan, J. A., Hills, A., Davis, M., et al. (2009) · Nature Genetics

Genetic Associations and EpidemiologyGenomics and Chromatin Dynamics

Cited by 663

Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchHedgehog Signaling Pathway Studies

Cited by 561

Management and Preparedness for Infusion and Hypersensitivity Reactions

Lenz, H.-J. (2007) · The Oncologist

Drug-Induced Adverse ReactionsMonoclonal and Polyclonal Antibodies Research

Cited by 479

Mutational Analysis of Patients with Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 317

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

André, T., Elez, E., Van Cutsem, E., Jensen, L. H., Bennouna, J., Mendez, G., Schenker, M., de la Fouchardiere, C., Limon, M. L., Yoshino, T., et al. (2024) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 286

The current state of molecular testing in the treatment of patients with solid tumors, 2019

El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 264

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial

André, T., Elez, E., Lenz, H.-J., Jensen, L. H., Touchefeu, Y., Van Cutsem, E., Garcia-Carbonero, R., Tougeron, D., Mendez, G. A., Schenker, M., et al. (2025) · The Lancet

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 256

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)

Lenz, H.-J., Ou, F.-S., Venook, A. P., Hochster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Bertagnolli, M. M., Blanke, C. D., Zemla, T., et al. (2019) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 246

Molecular determinants of cetuximab efficacy.

Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 234

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 232

Molecular Insight of Regorafenib Treatment for Colorectal Cancer

Arai, H., Battaglin, F., Wang, J., Lo, J. H., Soni, S., Zhang, W., & Lenz, H.-J. (2019) · Cancer Treatment Reviews

Colorectal Cancer Treatments and StudiesAngiogenesis and VEGF in Cancer

Cited by 191

Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 112

Molecular pathways: cachexia signaling-A targeted approach to cancer treatment

Miyamoto, Y., Hanna, D. L., Zhang, W., Baba, H., & Lenz, H.-J. (2016) · Clinical Cancer Research

Muscle Physiology and DisordersNutrition and Health in Aging

Cited by 111

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

Van Schaeybroeck, S., Kalimutho, M., Dunne, P. D., Carson, R., Allen, W., Jithesh, P. V., Redmond, K. L., Sasazuki, T., Shirasawa, S., Blayney, J., et al. (2014) · Cell Reports

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 106

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

LaBonte, M. J., Wilson, P. M., Fazzone, W., Groshen, S., Lenz, H.-J., & Ladner, R. D. (2009) · BMC Medical Genomics

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 99

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells

Fazzone, W., Wilson, P. M., LaBonte, M. J., Lenz, H., & Ladner, R. D. (2009) · International Journal of Cancer

Histone Deacetylase Inhibitors ResearchColorectal Cancer Treatments and Studies

Cited by 80